RxDoctor Payments Data

Hannah Cecil

Family · Griffin, GANPI 1629243480

Payments from drug & device makers

$870in general payments, 2019–2025

Across 49 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$246
  • Novo Nordisk$142
  • Bayer$86
  • Sanofi-aventis U.S. LLC$77
  • AbbVie$68
  • AstraZeneca$51
  • plus $200 from 9 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$870 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$89,303
Medicare patients
113
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$76,539
OzempicSemaglutide60$73,624
LinzessLinaclotide91$72,773
FarxigaDapagliflozin Propanediol67$68,935
EliquisApixaban51$55,356
JardianceEmpagliflozin60$43,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$38,876
KerendiaFinerenone35$37,353
RybelsusSemaglutide13$24,830
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$24,677
Synjardy XrEmpagliflozin/Metformin Hcl29$23,992
GlyxambiEmpagliflozin/Linagliptin20$23,187
JanuviaSitagliptin Phosphate16$20,725
TradjentaLinagliptin14$16,609
Tresiba Flextouch U-200Insulin Degludec20$15,608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta$30$107,501123 claims
Novo NordiskOzempic, Rybelsus$142$98,45473 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$51$90,439112 claims
Lilly USA, LLCMounjaro$246$76,53964 claims
AbbVieLinzess$68$72,77391 claims
PfizerEliquis$13$55,35651 claims
BayerKerendia$86$37,35335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.

Other family in Griffin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →